
News|Articles|February 13, 2019
Daurismo for Newly Diagnosed AML
Author(s)Drew Boxler
Advertisement
Daurismo (glasdegib, Pfizer)
Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy
Dosage: 100 mg orally, once daily.
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Panel to Evaluate 7 Popular Peptides for Compounding Substances List
2
Large Language Models Support Antimicrobial Stewardship Pharmacy Services
3
West Nile Virus Activity Climbs in 2026, Primarily Impacting Arizona
4
How GLP-1 Therapies Could Impact Bone Density, Muscle Loss
5































